Anti-GAL9 immune-oncology axis for cancer therapy
Researchers at QIMR Berghofer have identified a novel immune regulatory axis, which acts through the modulation of GAL9 on both T-cells and dendritic cells. Using selective antibodies, they have demonstrated that GAL9 modulation disrupts checkpoint molecules and drives activated T-cells toward a Th1 effector type.
Unique selling point/competitive advantage
Through their unique understanding of GAL9 biology, QIMR Berghofer's researchers have identified the therapeutic potential of this previously identified but poorly understood immune checkpoint molecule. In vitro immune activation and in vivo efficacy data demonstrate the therapeutic potential of this novel checkpoint axis. Critically, the research team have completed discovery and validation of fully human, highly characterised lead monoclonal antibodies with demonstrated in vitro activity superior to their tool antibodies.
Investment or collaboration opportunities
QIMR Berghofer is exploring both licensing and investment opportunities to drive further development of this program.
Intellectual property rights
QIMR Berghofer has 3 patent applications—2 in Patent Cooperation Treaty (PCT) and 1 in national phase—covering the use of GAL9 modifying agents for therapy and as a companion diagnostic or predictive test.
Dr. Robert McLachlan
Head of Business Development
Phone: +61 407 371 096
Visit QIMR Berghofer for more information.
- Last reviewed: 17 Jul 2019
- Last updated: 29 May 2018